Clinical Trial Update: A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection

View source ↗

Summary

A clinical trial evaluating rilpivirine hydrochloride (Edurant) for adults with HIV-1 infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Edurant (rilpivirine)

Snippet

Sponsor: Janssen Pharmaceutica | Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Status: WITHDRAWN